TELA BIO INC (TELA)
US8723811084 - Common Stock
Overall TELA gets a fundamental rating of 3 out of 10. We evaluated TELA against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of TELA have multiple concerns. TELA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
TELA had negative earnings in the past year.
TELA had a negative operating cash flow in the past year.
TELA had negative earnings in each of the past 5 years.
TELA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
TELA's Return On Assets of -69.95% is on the low side compared to the rest of the industry. TELA is outperformed by 77.01% of its industry peers.
TELA has a worse Return On Equity (-1467.28%) than 90.37% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.95% | ||
| ROE | -1467.28% | ||
| ROIC | N/A |
ROA(3y)-59.43%
ROA(5y)-51.21%
ROE(3y)-240.76%
ROE(5y)-175.72%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TELA has a better Gross Margin (68.62%) than 78.61% of its industry peers.
TELA's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for TELA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.62% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.63%
GM growth 5Y14.06%
2. Health
2.1 Basic Checks
TELA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TELA has been increased compared to 1 year ago.
Compared to 5 years ago, TELA has more shares outstanding
Compared to 1 year ago, TELA has an improved debt to assets ratio.
2.2 Solvency
TELA has an Altman-Z score of -7.53. This is a bad value and indicates that TELA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TELA (-7.53) is worse than 75.40% of its industry peers.
A Debt/Equity ratio of 14.22 is on the high side and indicates that TELA has dependencies on debt financing.
With a Debt to Equity ratio value of 14.22, TELA is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 14.22 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.53 |
ROIC/WACCN/A
WACC9.88%
2.3 Liquidity
TELA has a Current Ratio of 3.41. This indicates that TELA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.41, TELA is in line with its industry, outperforming 58.82% of the companies in the same industry.
A Quick Ratio of 2.52 indicates that TELA has no problem at all paying its short term obligations.
TELA has a Quick ratio of 2.52. This is comparable to the rest of the industry: TELA outperforms 57.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.41 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
TELA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.96%, which is quite good.
Looking at the last year, TELA shows a very strong growth in Revenue. The Revenue has grown by 41.12%.
TELA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 47.86% yearly.
EPS 1Y (TTM)17.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%6.67%
Revenue 1Y (TTM)41.12%
Revenue growth 3Y47.51%
Revenue growth 5Y47.86%
Sales Q2Q%25.94%
3.2 Future
The Earnings Per Share is expected to grow by 22.89% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 28.63% on average over the next years. This is a very strong growth
EPS Next Y30.3%
EPS Next 2Y29.02%
EPS Next 3Y21.62%
EPS Next 5Y22.89%
Revenue Next Year29.1%
Revenue Next 2Y27.18%
Revenue Next 3Y26.61%
Revenue Next 5Y28.63%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TELA. In the last year negative earnings were reported.
Also next year TELA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
TELA's earnings are expected to grow with 21.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.02%
EPS Next 3Y21.62%
5. Dividend
5.1 Amount
No dividends for TELA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELA BIO INC
NASDAQ:TELA (11/22/2024, 8:07:58 PM)
3.01
+0.12 (+4.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap110.41M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -69.95% | ||
| ROE | -1467.28% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 68.62% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 14.22 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.41 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)17.96%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y30.3%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)41.12%
Revenue growth 3Y47.51%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y